Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q4736710> ?p ?o }
Showing triples 1 to 37 of
37
with 100 triples per page.
- Q4736710 subject Q52319.
- Q4736710 subject Q7158322.
- Q4736710 subject Q7335370.
- Q4736710 subject Q8808791.
- Q4736710 subject Q9429485.
- Q4736710 abstract "Altinicline (SIB-1508Y, SIB-1765F) is a drug which acts as an agonist at neural nicotinic acetylcholine receptors with high selectivity for the α4β2 subtype. It stimulates release of dopamine and acetylcholine in the brain in both rodent and primate models, and progressed as far as Phase II clinical trials for Parkinson's disease, where "no antiparkinsonian or cognitive-enhancing effects were demonstrated", although its current status is unclear.".
- Q4736710 atcPrefix "None".
- Q4736710 casNumber "179120-92-4".
- Q4736710 fdaUniiCode "RJ9V9V09VM".
- Q4736710 iupacName "(2S)-3-ethynyl-5-(1-methylpyrrolidin-2-yl)pyridine".
- Q4736710 pubchem "3036156".
- Q4736710 thumbnail Altinicline_structure.png?width=300.
- Q4736710 wikiPageWikiLink Q11085.
- Q4736710 wikiPageWikiLink Q170304.
- Q4736710 wikiPageWikiLink Q180623.
- Q4736710 wikiPageWikiLink Q30612.
- Q4736710 wikiPageWikiLink Q389934.
- Q4736710 wikiPageWikiLink Q412256.
- Q4736710 wikiPageWikiLink Q4734895.
- Q4736710 wikiPageWikiLink Q52319.
- Q4736710 wikiPageWikiLink Q7158322.
- Q4736710 wikiPageWikiLink Q7335370.
- Q4736710 wikiPageWikiLink Q8808791.
- Q4736710 wikiPageWikiLink Q9429485.
- Q4736710 atcPrefix "None".
- Q4736710 casNumber "179120".
- Q4736710 iupacName "-3".
- Q4736710 pubchem "3036156".
- Q4736710 unii "RJ9V9V09VM".
- Q4736710 type ChemicalSubstance.
- Q4736710 type Drug.
- Q4736710 type ChemicalObject.
- Q4736710 type Thing.
- Q4736710 type Q8386.
- Q4736710 comment "Altinicline (SIB-1508Y, SIB-1765F) is a drug which acts as an agonist at neural nicotinic acetylcholine receptors with high selectivity for the α4β2 subtype. It stimulates release of dopamine and acetylcholine in the brain in both rodent and primate models, and progressed as far as Phase II clinical trials for Parkinson's disease, where "no antiparkinsonian or cognitive-enhancing effects were demonstrated", although its current status is unclear.".
- Q4736710 label "Altinicline".
- Q4736710 depiction Altinicline_structure.png.